丹红注射液联合瑞舒伐他汀对急性心肌梗死PCI术后心肌无复流及IL-6、Cys-C、Hcy的影响

Effects of Danhong Injection Combined with Rosuvastatin on Myocardial No-reflow and IL-6,Cys-C and Hcy in Patients with Acute Myocardial Infarction after PCI

目的探讨丹红注射液联合瑞舒伐他汀对急性心肌梗死经皮冠状动脉介入治疗(PCI)术后心肌无复流及白细胞介素-6(IL-6)、胱抑素-C(Cys-C)、同型半胱氨酸(Hcy)的影响。方法将126例急性心肌梗死PCI术后病人按抽签法分为对照组和试验组,每组63例。对照组予以瑞舒伐他汀治疗,试验组在对照组基础上加用丹红注射液治疗。比较两组心肌无复流情况、IL-6、Cys-C、Hcy、心功能及心血管事件发生率。结果试验组心肌无复流率为6.35%(4/63),低于对照组的25.40%(16/63),差异有统计学意义(P<0.05)。治疗后,两组IL-6、Cys-C、Hcy均较治疗前下降,但试验组显著低于对照组[(48.76±6.04)ng/L与(59.35±7.32)ng/L,(0.53±0.06)mg/L与(1.15±0.14)mg/L,(5.79±0.71)μmol/L与(12.24±1.50)μmol/L],差异有统计学意义(P<0.05)。两组治疗后左室射血分数(LVEF)均较治疗前上升(P<0.05),但试验组高于对照组[(55.20±6.93)%与(51.23±6.45)%,P<0.05],两组治疗后左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)均较治疗前下降(P<0.05),但试验组低于对照组[(30.21±3.76)mm与(34.59±4.19)mm,(46.31±5.65)mm与(50.76±6.15)mm],差异有统计学意义(P<0.05)。试验组心血管事件发生率低于对照组(7.94%与26.98%,P<0.05)。结论丹红注射液联合瑞舒伐他汀能够改善急性心肌梗死PCI术后心肌无复流,降低IL-6、Cys-C、Hcy,改善心功能,降低心血管事件发生率。

Objective To investigate the effects of Danhong injection （DHI） combined with rosuvastatin on myocardial no reflow andinterleukin 6 （IL 6）,cystatin C （Cys C）,and homocysteine （Hcy） in patients with acute myocardial infarction （AMI） after percutane -ous coronary intervention （PCI）.Methods One hundred and twenty six patients with AMI after PCI were divided into two groups ac -cording to lottery method：control group （ n =63） treated with rosuvastatin and treatment group （ n =63） treated with DHI and rosuvas -tatin.The myocardial no reflow,IL 6,Cys C,Hcy,cardiac function,and cardiovascular events were observed.Results The myocardi-al no reflow rate in treatment group was 6.35%,which was lower than that in control group （25.40%, P 〈0.05）.After treatment, thelevels of IL 6,Cys C and Hcy decreased in two groups,which were significantly lower in treatment group than those in control group[ （48.76±6.04） ng/L vs （59.35±7.32） ng/L,（0.53±0.06） mg/L vs （1.15±0.14） mg/L,（5.79±0.71）μmol/L vs （12.24±1.50）μmol/L,P 〈0.05] .The left ventricular ejection fraction increased in two groups after treatment （P 〈0.05）,which was higher in treatment group than that[ ]〈in control group [ （55.20±6.93）% vs （51.23±6.45）%,P 〈0.05] .The left ventricular end systolic diameter and left ventricular end dias -tolic diameter were decreased after treatment （P 〈0.05）,which were lower in treatment group than those in control group [ （30.21±3.76）mm vs （34.59±4.19） mm,（46.31±5.65） mm vs （50.76±6.15）mm,P 〈0.05] .The incidence of cardiovascular events in treatment groupwas lower than that in the control group （7.94% vs 26.98%,P 〈0.05）.Conclusion DHI and rosuvastatin can improve myocardial noreflow after PCI in AMI,reduce IL 6,Cys C and Hcy,improve cardiac function and reduce the incidence of cardiovascular events.